Drug Profile
Deudextromethorphan - Avanir Pharmaceuticals
Alternative Names: AVP-786; CTP-786; d-DM; Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]; Deuterated dextromethorphan plus ultra low dose quinidine; Deuterated DM plus ultra low dose quinidine; Deuterated-dextromethorphan; Deuterated-DMLatest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator Concert Pharmaceuticals
- Developer Avanir Pharmaceuticals
- Class Antidepressants; Antipsychotics; Antitussives; Behavioural disorder therapies; Morphinans; Neuroprotectants; Opioid analgesics; Organic deuterium compounds; Small molecules
- Mechanism of Action Cytochrome P 450 enzyme system inhibitors; KATP channel inhibitors; NMDA receptor antagonists; Norepinephrine plasma membrane transport protein inhibitors; Serotonin plasma membrane transport protein inhibitors; Sigma-1 receptor agonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Agitation
- Phase II/III Schizophrenia
- Phase II Impulse control disorders; Major depressive disorder; Neurodegenerative disorders
- No development reported Neuropathic pain; Psychiatric disorders
Most Recent Events
- 12 Feb 2024 Efficacy and adverse event data from a phase III trial in Agitation released by Otsuka Pharmaceutical
- 14 Dec 2023 Otsuka Pharmaceutical Development & Commercialization completes a phase III trial in Agitation in USA (PO) (NCT03393520)
- 23 May 2023 Otsuka Pharmaceutical Development & Commercialization terminates phase-II/III trial in Schizophrenia (In adults) in Puerto Rico, Poland, Hungary, Bulgaria, Spain and USA (PO) based on the interim analysis outcome and recommendation by the data monitoring committee (DMC) (NCT03896945)